Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene, Alliance Global Sign Distribution Deal for Middle East, Africa

NEW YORK – UK-based molecular diagnostics company Yourgene said on Wednesday that it is has signed a distribution deal with Dubai-based Alliance Global to sell its products in several territories in the Middle East and Africa.

Financial terms of the deal were not disclosed.

Yourgene said the partnership will expand its geographical footprint and its customer base. Alliance Global has worked with many providers of both PCR and sequencing technologies that were looking to bring their products to the Middle East, Africa, and Asia. The company will be distributing Yourgene's product portfolio of noninvasive prenatal testing; reproductive health tests, including cystic fibrosis and QST*R rapid aneuploidy analysis; DPYD genotyping; and its new size selection and enrichment technologies, Yourgene QS250 and LightBench.

"This partnership with [Alliance Global] is a really exciting progression for Yourgene and our product portfolio as we continue to expand into further territories," Yourgene CEO Lyn Rees said in a statement. "[Alliance Global] will provide a strong and well-positioned channel to allow us to deliver and drive growth for our current and future products. This is a key international market for Yourgene."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.